TRIM3 exacerbates chondrocyte apoptosis through suppression of AKT/mTOR signaling pathway in osteoarthritis Authors: Huashuang Ou, Baichuan Li, Haibo Liang, Haiquan Deng, Lei Zhang, Mindong Lan, Xiangrong Cui, Shuzhen Li, Jianchao Sun Published: 2025 ABSTRACT IntroductionAs a leading cause of disability worldwide, osteoarthritis (OA) progressively degrades articular cartilage. The incomplete understanding of OA's molecular mechanisms hinders development of disease-modifying treatments.MethodsWe analyzed GEO database knee OA datasets to track TRIM3 expression dynamics throughout disease progression. Western blot and IHC quantified TRIM3 protein differences between OA and normal cartilage. TRIM3-knockdown chondrocytes showed altered Bcl-2/Bax ratios via qRT-PCR/Western blot, with p-AKT/p-mTOR levels indicating AKT/mTOR activation. To establish functional dependency, siTRIM3 cells were treated with mTOR inhibitor followed by reevaluation of Bcl-2/Bax balance. Apoptotic responses to IL-1β stimulation were quantified by flow cytometry, while collagen II (COL2A1) preservation was visualized via immunofluorescence.ResultsIntegrated bioinformatics and IHC analyses demonstrated significant TRIM3 upregulation in OA cartilage compared to healthy controls (P = 0.043). TRIM3 depletion exerted dual protective effects: (1) modulating apoptotic regulators by decreasing Bax while increasing Bcl-2 expression, and (2) enhancing AKT/mTOR pathway activation evidenced by elevated p-AKT/p-mTOR levels.Notably, mTOR inhibition abolished these effects, restoring pro-apoptotic Bax expression and suppressing anti-apoptotic Bcl-2 (p < 0.01), confirming pathway mediation. Functionally, siTRIM3 conferred 40% reduction in IL-1β-induced apoptosis (P = 0.0081) and remarkably preserved COL2A1 integrity, exhibiting 2.3-fold higher fluorescence intensity versus controls.ConclusionOur findings establish TRIM3 as a novel regulator of OA pathogenesis that exacerbates disease progression through AKT/mTOR pathway suppression, thereby promoting chondrocyte apoptosis and extracellular matrix degradation. Therapeutic targeting of TRIM3 may represent a promising strategy to attenuate cartilage degeneration in OA. Introduction Osteoarthritis (OA), as a highly prevalent chronic degenerative joint disease, represents the leading global cause of chronic pain and functional disability. Its pathological hallmarks include progressive cartilage degradation, synovial inflammation, and periarticular tissue remodeling (encompassing osteophyte formation and subchondral bone sclerosis) [1–3]. Articular cartilage, a connective tissue composed of chondrocytes and their secreted extracellular matrix (ECM), provides essential lubrication and biomechanical support for joint function. Notably, OA pathophysiology is closely associated with dysregulated chondrocyte autophagy [3], where aberrant activation of the PI3K/AKT/mTOR signaling pathway—a critical regulator of autophagy—can suppress chondrocyte autophagy while promoting apoptosis [4, 5]. Although chondrocytes constitute merely 1% of total cartilage volume, they serve as central regulators of ECM homeostasis. Current evidence indicates that inflammatory cytokines like IL-1β activate the PI3K/AKT/mTOR pathway to concurrently induce chondrocyte apoptosis and autophagy inhibition [5, 6], a dual effect that accelerates OA progression. Despite advances in symptomatic management, existing therapies remain palliative, failing to effectively decelerate disease progression, control persistent synovitis, or restore dysfunctional chondrocytes. Thus, elucidating its pathogenesis is crucial for identifying molecular targets for disease-modifying interventions. The TRIM protein family, a group of ubiquitous multifunctional proteins, plays pivotal roles in cellular regulation and disease pathogenesis. Family members typically modulate intracellular signaling pathways to influence cell growth, proliferation, differentiation, and survival [7–9]. TRIM3 (also termed Ro52/TSS-62), a key member of the TRIM (tripartite motif) family, harbors characteristic RING, B-box, and coiled-coil domains that confer functional versatility and interaction capacity [10–12]. Emerging studies demonstrate TRIM3’s involvement in critical biological processes including apoptosis [10], cell cycle progression, migration, and proteasomal degradation. Significantly, other TRIM family members have been implicated in chondrocyte metabolism: for instance, TRIM15 is markedly upregulated in senescent chondrocytes from OA patients and contributes to OA progression by promoting cellular senescence [13], while TRIM8 and TRIM59 regulate ECM metabolism [14, 15]. These findings underscore the TRIM family’s regulatory importance in cartilage homeostasis and OA development. However, research linking TRIM3 to arthritis remains scarce. While TRIM3's role in rheumatoid arthritis (RA) has been preliminarily investigated (showing downregulation in RA synovial tissue compared to controls) [16], its function in osteoarthritis (OA) pathogenesis remains unclear. Specifically, it is unknown whether TRIM3 affects chondrocyte apoptosis and autophagy through AKT/mTOR pathway modulation. [5, 17, 18]. This knowledge gap obscures its mechanistic role in cartilage degeneration. This study investigates TRIM3’s expression patterns and functional impact on OA-associated chondrocyte apoptosis, while delineating its regulatory relationship with the AKT/mTOR pathway during OA progression. Given that the AKT/mTOR pathway serves as a master regulator of both apoptosis and autophagy [5, 17, 19], its aberrant activation disrupts chondrocyte homeostasis [4, 20]. Our findings not only deepen understanding of programmed cell death mechanisms but also nominate TRIM3 as a potential therapeutic target for OA treatment and drug development. Methods GEO transcriptomic analysis of TRIM3 in knee osteoarthritis (KOA) Transcriptomic and clinical data related to knee osteoarthritis (KOA) were retrieved from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.govgeo). The GSE114007 dataset included 18 normal cartilage samples and 20 KOA cartilage samples. Raw data were processed using R software (v4.3.1) to integrate clinical metadata and generate expression matrices. Perl scripts were employed to filter mRNA expression profiles by removing non-coding RNA data. For external validation, the GEO database was queried using the keyword "knee osteoarthritis" with species restricted to Homo sapiens, yielding the GSE113825 dataset comprising 5 KOA and 5 normal cartilage samples. Transcriptomic and clinical data from GSE113825 were downloaded via R packages (GEOquery), and probe IDs were annotated to standardized gene symbols. Combined with GSE114007 data, raw transcriptomic data underwent preprocessing steps, including background correction (RMA algorithm) and quantile normalization (limma package), to ensure comparability across datasets. Patients and tissue samples Normal cartilage tissues (control group, n = 3) were obtained from amputated limbs of three trauma patients. Degenerative cartilage samples (OA group) were collected from four osteoarthritis patients undergoing total joint replacement surgery. One OA sample was excluded due to unsuccessful protein extraction, resulting in a final analyzed OA group sample size of n = 3. (Table 1). Fresh tissues from the included samples were preserved either on ice (for immediate protein extraction) or in formalin (for subsequent immunohistochemical analysis). Patient age and sex information were not systematically recorded for this study. Written informed consent was acquired preoperatively from all participants. This study protocol was approved by the Medical Ethics Committee of The People's Hospital of Guangxi Zhuang Autonomous Region (Guangxi Academy of Medical Sciences) (Approval No. KY-KJT-2023-25).Table 1Patient's basic informationNameGender (M/F)Age (years)BMI (kg/m2)OA Grade (K-L Classification)NormalW.J.CM6922.10H.H.FM6521.50M.J.GF7028.80OAF.MF5529.13P.X.LF7123.64P.X.YF6628.54 Table 1Patient's basic informationNameGender (M/F)Age (years)BMI (kg/m2)OA Grade (K-L Classification)NormalW.J.CM6922.10H.H.FM6521.50M.J.GF7028.80OAF.MF5529.13P.X.LF7123.64P.X.YF6628.54 Patient's basic information Rat chondrocyte isolation and culture Sprague–Dawley (SD) rats were supplied by the Experimental Animal Center of Guangxi Medical University. All experimental procedures were approved by the Experimental Ethics Committee of The People's Hospital of Guangxi Zhuang Autonomous Region (Guangxi Academy of Medical Sciences) (Approval No. KY-KJT-2023-25). Chondrocytes were isolated from rat articular cartilage using enzymatic digestion methods as previously described in the literature [21]. Cell culture and subculturing were performed according to protocols established in our prior studies [22]. SiRNA transfection siRNA Design and Preparation: TRIM3-specific siRNA duplexes (target sequence: 5′-GCAGCACAAGGCAGCUCUA-3′) or mTOR-specific siRNA duplexes (target sequence: 5′-GCCGCAUAGUCUCCAUCAA-3′) and negative control siRNA (scrambled sequence, non-targeting) were synthesized by RiboBio (Guangzhou, China). Stock solutions (20 μM) were prepared in RNase-free water and stored at −80 °C. Cell Seeding: Rat chondrocytes were seeded in 6-well plates at a density of 5 × 105 cells/well and cultured in DMEM/F12 (10% FBS, 1% penicillin–streptomycin) until reaching 70–80% confluence (24 h after seeding), ensuring optimal transfection efficiency. Transfection Reagent and Complex Preparation: Lipofectamine 3000 (Invitrogen, L3000015) was used as the transfection reagent, following the manufacturer’s protocol with minor optimization. For each well: 5 μL Lipofectamine 3000 was diluted in 125 μL Opti-MEM (serum-free), and 5 μL P3000 reagent was mixed with 50 pmol TRIM3 siRNA (or negative control siRNA) in 125 μL Opti-MEM. The two mixtures were combined, incubated at room temperature for 15 min to form lipoplexes. Transfection Induction: The culture medium of chondrocytes was replaced with 1.75 mL Opti-MEM (serum-free), and the lipoplex mixture (250 μL/well) was added dropwise. Cells were incubated at 37 °C with 5% CO₂ for 6 h, after which the medium was replaced with fresh DMEM/F12 (10% FBS) to reduce cytotoxicity. Knockdown Efficiency Verification: At 48 h post-transfection, total RNA and protein were extracted. TRIM3 or mTOR mRNA expression was detected by qRT-PCR, and protein level by Western blot, confirming > 70% knockdown efficiency in both mRNA and protein levels. Subsequent Inflammatory Stimulation: After verifying knockdown efficiency (48 h post-transfection), chondrocytes were treated with 10 ng/mL IL-1β (to mimic OA inflammatory microenvironment) for 24 h, followed by detection of apoptosis (Annexin V/PI staining) and ECM-degrading enzymes (by Western blot/qRT-PCR). RNA extraction and quantitative real-time PCR (qRT-PCR) Total RNA was isolated from cultured chondrocytes using TRIzol reagent (Takara Bio, Dalian, China) following the manufacturer’s protocol. RNA concentration was quantified spectrophotometrically (NanoDrop 2000, Thermo Fisher Scientific), and residual genomic DNA was removed using DNase I (RNase-free). DNA-free RNA was reverse-transcribed into cDNA using a PrimeScript RT Master Mix (Takara Bio). qRT-PCR reactions (10μL total volume) contained 1μL cDNA, 5μL TB Green Premix Ex Taq II (Takara Bio), and 0.5μL each of forward/reverse primers (10 μM). Thermal cycling conditions on a Light Cycler 96 system (Roche Diagnostics GmbH, Germany) included:Initial denaturation: 95 °C for 30 s. 40 cycles of: 95 °C for 10 s (denaturation), 60 °C for 40 s (annealing/extension). GAPDH served as the endogenous control. Relative gene expression was calculated using the 2^(−ΔΔCt)) method, normalized to GAPDH. All primers and siRNAs were designed and synthesized by Nanning Gensys Biotechnology Co., Ltd. (China) (Table 2).Table 2Primer and siRNA SequencesTargetSequence (5′ → 3′)TRIM3Forward: GATAAGTGCAGCCTTTGAGGReverse: CAGTGCCTGCTCTGCAAAGCBaxForward: CCAAGAAGCTGAGCGAGTGTReverse: CCAGTTGAAGTTGCCGTCTGBcl-2Forward: CTCTACGGCCCCTTGTCGReverse: GTGAAGGGCGTCAGGTGCAGGAPDHForward: TCTCTGCTCCTCCCTGTTCReverse: ACACCGACCTTCACCATCTmTORForward: AGACACCATGAACCATGCCReverse: TGTGGCATCCACCTGCACAGsiTRIM3Target: GCAGCACAAGGCAGCUCUA (rat-specific)simTORTarget: GCCGCAUAGUCUCCAUCAA (rat-specific) Table 2Primer and siRNA SequencesTargetSequence (5′ → 3′)TRIM3Forward: GATAAGTGCAGCCTTTGAGGReverse: CAGTGCCTGCTCTGCAAAGCBaxForward: CCAAGAAGCTGAGCGAGTGTReverse: CCAGTTGAAGTTGCCGTCTGBcl-2Forward: CTCTACGGCCCCTTGTCGReverse: GTGAAGGGCGTCAGGTGCAGGAPDHForward: TCTCTGCTCCTCCCTGTTCReverse: ACACCGACCTTCACCATCTmTORForward: AGACACCATGAACCATGCCReverse: TGTGGCATCCACCTGCACAGsiTRIM3Target: GCAGCACAAGGCAGCUCUA (rat-specific)simTORTarget: GCCGCAUAGUCUCCAUCAA (rat-specific) Primer and siRNA Sequences Forward: GATAAGTGCAGCCTTTGAGG Reverse: CAGTGCCTGCTCTGCAAAGC Forward: CCAAGAAGCTGAGCGAGTGT Reverse: CCAGTTGAAGTTGCCGTCTG Forward: CTCTACGGCCCCTTGTCG Reverse: GTGAAGGGCGTCAGGTGCAG Forward: TCTCTGCTCCTCCCTGTTC Reverse: ACACCGACCTTCACCATCT Forward: AGACACCATGAACCATGCC Reverse: TGTGGCATCCACCTGCACAG Protein extraction and western blotting Total proteins were extracted from cultured chondrocytes. Briefly, cells were washed thrice with PBS and lysed in ice-cold RIPA buffer (CWBIO, China) containing 1% protease and phosphatase inhibitors for 30 min. Protein concentration was determined using a BCA assay kit, followed by denaturation with SDS-PAGE loading buffer (EpiZyme, Shanghai, China) at 95 °C for 10 min. Equal amounts of proteins (20–50 μg) were resolved on 8–12% SDS–polyacrylamide gels (Beyotime, China) and transferred to PVDF membranes (Millipore, USA).Membranes were blocked with 5% BSA in TBST (10 mM Tris [pH 8.0], 150 mM NaCl, 0.1% Tween-20) for 1 h at room temperature, then incubated overnight at 4 °C with primary antibodies. After three TBST washes, membranes were incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. Protein bands were visualized using enhanced chemiluminescence (ECL) reagents and quantified by ImageJ (NIH, USA). Protein expression was normalized to GAPDH as the internal control. Antibodies:Anti-Col2a1, anti-TRIM3, anti-p-mTOR, anti-Bax, anti-Bcl-2, anti-p-AKT (Abcam, UK); Anti-GAPDH (Proteintech, USA). Immunohistochemistry (IHC) Human bone tissue specimens were fixed in 4% neutral buffered formalin, paraffin-embedded, and sectioned at 5 μm thickness. Following deparaffinization in xylene and rehydration through graded ethanol series, antigen retrieval was performed using citrate buffer (pH 6.0) under microwave heating. Sections were then treated with 3% hydrogen peroxide for 15 min at room temperature to block endogenous peroxidase activity, followed by 30 min incubation with 10% normal goat serum to reduce nonspecific binding. The sections were incubated overnight at 4 °C with primary anti-TRIM3 antibody (1:100 dilution, Abcam, UK). After washing, biotin-conjugated goat anti-rabbit IgG secondary antibody (1:500) and streptavidin–horseradish peroxidase (HRP) complex were applied for 1 h at room temperature. Diaminobenzidine (DAB) substrate was used for chromogenic detection, and nuclei were counterstained with hematoxylin. Apoptosis analysis by flow cytometry Rat chondrocytes transfected with siTRIM3 were treated with 10 ng/mL IL-1β (Peprotech, USA) for 24 h. Cells were then harvested by trypsinization, centrifuged at 1000 rpm for 5 min, and washed twice with PBS. The cell pellet was resuspended in 400μL × Annexin V Binding Buffer (BD Biosciences). Cells were divided into two aliquots:Experimental group: Stained with 5μL Annexin V-FITC (light-protected, 15 min at room temperature), followed by 10μL propidium iodide (PI). Unstained control: No dye added. Samples were analyzed immediately on a flow cytometer using 488 nm excitation. Apoptotic rates were calculated as the percentage of Annexin V + /PI − (early apoptosis) and Annexin V + /PI + (late apoptosis) cells. Immunofluorescence (IF) Cultured rat chondrocytes were washed three times with PBS and fixed with 4% paraformaldehyde for 30 min at room temperature. After three additional PBS washes, cells were permeabilized with 0.5% Triton X-100 for 10 min. Non-specific binding was blocked with 10% normal goat serum for 1 h at room temperature. Primary antibody (anti-Col2a1, 1:100 dilution, Immunoway, Suzhou, China) was applied and incubated overnight at 4 °C. Following three PBS washes, cells were incubated with a Cy3-conjugated goat anti-rabbit IgG secondary antibody (1:100, Boshi Biotechnology, China) under light-protected conditions for 1 h at room temperature. Nuclei were counterstained with DAPI (0.1 μg/mL) for 4 min. After final PBS washes, fluorescence images were captured using an Olympus IX73 inverted fluorescence microscope (Tokyo, Japan) with appropriate filter sets. Data analysis Data are presented as the mean ± standard deviation (SD) from at least three independent experiments. Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software, USA). Parametric data (normally distributed) were analyzed by Student’s t -test (for two-group comparisons) or one-way analysis of variance (ANOVA, for multi-group comparisons). Differences were considered statistically significant at p < 0.05. Results TRIM3 targets differentially expressed genes associated with knee osteoarthritis Clinical and transcriptomic data related to knee osteoarthritis (KOA) were downloaded from the GEO database. Clinical data were processed and integrated using R software. Analysis revealed that TRIM3 was significantly upregulated in KOA patients (Fig. 1A and B). Differentially expressed mRNAs (DEGs) were screened using thresholds of p-value < 0.05 and |log2FC|≥ 0.50, identifying 5189 DEGs in the dataset. A heatmap of the KOA-TRIM3-related mRNA expression matrix was generated (Fig. 1C). Gene Set Enrichment Analysis (GSEA) of KOA-associated genes (ranked by log2FC) in the GSE114007 dataset revealed significant enrichment in pathways including:Complement and coagulation cascades. Protein digestion and absorption. Rheumatoid arthritis. Circadian rhythm. ECM-receptor interaction. (Fig. 1D). Correlation analysis of TRIM3-associated genes in KOA (filtered by |Cor|> 0.60 and p-value < 0.05) identified 1859 co-expressed genes.Fig. 1 TRIM3 Targets Differentially Expressed Genes Associated with Knee Osteoarthritis. Fig. 1A & B. Bar plots of TRIM3-targeted gene expression in knee osteoarthritis (Fig. 1A: Unmatched samples; Fig. 1B: Raincloud plot); Fig. 1C. Clustered heatmap of KOA-TRIM3-related differentially expressed genes; Fig. 1D. GSEA analysis of the GSE62872 gene set TRIM3 Targets Differentially Expressed Genes Associated with Knee Osteoarthritis. Fig. 1A & B. Bar plots of TRIM3-targeted gene expression in knee osteoarthritis (Fig. 1A: Unmatched samples; Fig. 1B: Raincloud plot); Fig. 1C. Clustered heatmap of KOA-TRIM3-related differentially expressed genes; Fig. 1D. GSEA analysis of the GSE62872 gene set TRIM3 expression is upregulated in osteoarthritis patients Western blot (WB) was performed to assess TRIM3 protein expression in cartilage tissues from OA patients and healthy controls. The results demonstrated that TRIM3 protein levels were significantly elevated in OA cartilage compared to healthy controls (P = 0.043; Fig. 2A). Immunohistochemical (IHC) analysis further corroborated these findings. TRIM3 expression was markedly higher in degenerated cartilage tissues from OA patients than in normal cartilage tissues (Fig. 2B).Fig. 2TRIM3 Expression Is Upregulated in Osteoarthritis PatientsWestern blotting revealed comparable TRIM3 expression between OA and normal cartilage tissues (Fig. 2A). IHC analysis showed a significantly increase in TRIM3 protein levels in osteoarthritic degenerative cartilage compared to normal counterparts (Fig. 2B) TRIM3 Expression Is Upregulated in Osteoarthritis PatientsWestern blotting revealed comparable TRIM3 expression between OA and normal cartilage tissues (Fig. 2A). IHC analysis showed a significantly increase in TRIM3 protein levels in osteoarthritic degenerative cartilage compared to normal counterparts (Fig. 2B) TRIM3 knockdown attenuates chondrocyte apoptosis To investigate whether TRIM3 regulates the expression of apoptosis-related genes in chondrocytes, primary rat chondrocytes transfected with TRIM3-targeting siRNA were analyzed by quantitative real-time PCR (qPCR). Compared to scrambled siRNA controls, TRIM3 siRNA induced > 70% knockdown of TRIM3 mRNA (P = 0.00014). Concurrently, mRNA levels of pro-apoptotic Bax and anti-apoptotic Bcl-2 were significantly downregulated (P = 0.00093 and P = 0.0096). Western blotting and densitometric quantification further confirmed dose-dependent suppression of TRIM3 protein (Fig. 3A–C).Fig. 3TRIM3 Knockdown Attenuates Chondrocyte ApoptosisWestern blot analysis (Fig. 3A) revealed that TRIM3 knockdown in rat chondrocytes significantly upregulated Bcl-2 protein expression while downregulating Bax levels (p < 0.05), as confirmed by densitometric quantification (Fig. 3B). Correspondingly, real-time PCR demonstrated a marked increase in Bcl-2 mRNA and decrease in Bax mRNA (p < 0.01) following TRIM3 silencing (Fig. 3C) TRIM3 Knockdown Attenuates Chondrocyte ApoptosisWestern blot analysis (Fig. 3A) revealed that TRIM3 knockdown in rat chondrocytes significantly upregulated Bcl-2 protein expression while downregulating Bax levels (p < 0.05), as confirmed by densitometric quantification (Fig. 3B). Correspondingly, real-time PCR demonstrated a marked increase in Bcl-2 mRNA and decrease in Bax mRNA (p < 0.01) following TRIM3 silencing (Fig. 3C) Inhibition of TRIM3 can promote the expression of p-AKT and p-mTOR To investigate whether TRIM3 modulates chondrocyte apoptosis via the AKT/mTOR signaling pathway, we analyzed the expression of phosphorylated AKT (p-AKT) and phosphorylated mTOR (p-mTOR) under TRIM3-knockdown conditions. Western blotting and quantitative densitometric analysis revealed that TRIM3 inhibition significantly upregulated p-AKT and p-mTOR protein levels (P = 0.0096 and P = 0.010) compared to scrambled siRNA controls (Fig. 4A and B).Fig. 4Inhibition of TRIM3 can promote the expression of p-AKT and p-mTORWestern blot analysis coupled with densitometric quantification revealed that TRIM3 knockdown significantly upregulated the phosphorylation levels of both mTOR and AKT (p < 0.05) Inhibition of TRIM3 can promote the expression of p-AKT and p-mTORWestern blot analysis coupled with densitometric quantification revealed that TRIM3 knockdown significantly upregulated the phosphorylation levels of both mTOR and AKT (p < 0.05) Targeted inhibition of the AKT/mTOR signaling axis induces chondrocyte apoptosis The AKT/mTOR signaling pathway exhibits a context-dependent role in regulating chondrocyte apoptosis. While hyperactivation of this pathway is generally associated with anti-apoptotic effects in various cell types, its specific regulatory mechanisms in chondrocyte apoptosis remain poorly characterized. To address this knowledge gap, we pharmacologically inhibited mTOR and analyzed apoptosis-related markers. Western blotting with densitometric quantification revealed that mTOR inhibition significantly downregulated the anti-apoptotic protein Bcl-2 (P = 0.006) while upregulating the pro-apoptotic protein Bax (P = 0.0037). Consistent results were observed at the transcriptional level through qPCR analysis (Fig. 5A–C).Fig. 5Targeted inhibition of the AKT/mTOR signaling axis induces chondrocyte apoptosisPharmacological mTOR inhibition substantially attenuated Bcl-2 protein expression while augmenting Bax levels (p < 0.01) as evidenced by WB with normalization to GADPH (Fig. 5A/B). This reciprocal regulation pattern was recapitulated at transcriptional level through qRT-PCR analysis, showing significantly reduction in Bcl2 mRNA and elevation in Bax transcripts (p < 0.05) (Fig. 5C) Targeted inhibition of the AKT/mTOR signaling axis induces chondrocyte apoptosisPharmacological mTOR inhibition substantially attenuated Bcl-2 protein expression while augmenting Bax levels (p < 0.01) as evidenced by WB with normalization to GADPH (Fig. 5A/B). This reciprocal regulation pattern was recapitulated at transcriptional level through qRT-PCR analysis, showing significantly reduction in Bcl2 mRNA and elevation in Bax transcripts (p < 0.05) (Fig. 5C) TRIM3 knockdown attenuates IL-1β-induced chondrocyte apoptosis Elevated IL-1β, a hallmark cytokine in osteoarthritic cartilage degeneration, was utilized to establish an inflammatory chondrocyte model (10 ng/mL,24 h). Flow cytometric analysis with Annexin V-FITC/PI dual staining revealed that IL-1β stimulation significantly increased the apoptotic rate compared to untreated controls (P = 0.0340). Notably, siRNA-mediated TRIM3 silencing markedly reduced IL-1β-induced apoptosis (P = 0.0081 vs. IL-1β + scramble siRNA group), demonstrating its anti-apoptotic regulatory role (Fig. 6A and B).Fig. 6TRIM3 Knockdown Attenuates IL-1β-Induced Chondrocyte ApoptosisFlow cytometry analysis revealed that IL-1β stimulation significantly increased the apoptotic rate compared to the untreated control group. Moreover, siRNA-mediated TRIM3 silencing markedly suppressed IL-1β-induced apoptosis. (Fig. 6A/B) TRIM3 Knockdown Attenuates IL-1β-Induced Chondrocyte ApoptosisFlow cytometry analysis revealed that IL-1β stimulation significantly increased the apoptotic rate compared to the untreated control group. Moreover, siRNA-mediated TRIM3 silencing markedly suppressed IL-1β-induced apoptosis. (Fig. 6A/B) TRIM3 suppression enhances collagen II biosynthesis in chondrocytes Emerging evidence indicates that collagen-mediated extracellular matrix (ECM)-cell interactions regulate chondrocyte survival through apoptosis signaling modulation. To investigate this interplay between TRIM3 and ECM homeostasis, chondrocytes were transfected with TRIM3-specific siRNA (50 nM, 48 h). Immunofluorescence analysis using a Col2a1 antibody demonstrated that TRIM3 knockdown significantly increased Col2a1 expression, with fluorescence intensity elevated by 2.3-fold compared to scramble siRNA controls (P < 0.05) (Fig. 7). This suggests TRIM3 acts as a negative regulator of cartilage-specific matrix biosynthesis.Fig. 7TRIM3 Suppression Enhances Collagen II Biosynthesis in ChondrocytesImmunofluorescence analysis revealed that TRIM3 knockdown significantly promoted Col2a1 expression. Compared to the negative control group (scramble siRNA), the fluorescence intensity increased by a significant 2.3-fold (P < 0.05) (Fig. 7) TRIM3 Suppression Enhances Collagen II Biosynthesis in ChondrocytesImmunofluorescence analysis revealed that TRIM3 knockdown significantly promoted Col2a1 expression. Compared to the negative control group (scramble siRNA), the fluorescence intensity increased by a significant 2.3-fold (P < 0.05) (Fig. 7) Discussion Osteoarthritis (OA), as the degenerative joint disease with the highest global disability rate, has been confirmed by multiple studies to involve abnormal activation of the PI3K/AKT/mTOR pathway in its pathogenesis [3, 20, 23].Our findings align with results showing that Tuina therapy alleviates cartilage degeneration by inhibiting this pathway [20], but contrast with the tumor cell model where TCP1 inhibits apoptosis via AKT/mTOR activation [17], suggesting tissue-specific regulatory patterns of this pathway in chondrocytes. Notably, while TRIM15 is also highly expressed in OA cartilage and promotes cellular senescence [13], TRIM3 exhibits unique pro-survival effects. This functional heterogeneity among TRIM family members may stem from their differential regulation of downstream signaling pathways. Regarding apoptosis regulation, our TRIM3 knockdown results sharply contrast with reports in breast cancer models where TRIM3 deletion induces apoptosis through p53 accumulation [10], yet partially overlap with mechanisms where SIRT3 overexpression reduces apoptosis by suppressing the PI3K/Akt/mTOR pathway [6, 24]. These regulatory discrepancies may reflect: 1) Cell-type dependency, as seen with TCP1 inhibiting apoptosis via AKT/mTOR activation in leukemia cells [17]; 2) Pathological stimulus specificity, where IL-1β-induced chondrocyte apoptosis is alleviated by 4-octyl itaconate (OI) through inhibition of the same pathway [5], while leptin suppresses autophagy via mTORC1 activation [3]. This suggests TRIM3 may function as an environmentally sensitive signaling node, with its ultimate effects determined by the overall balance of cytokine networks in the microenvironment. For ECM synthesis findings, our data align with studies showing NT3 maintains cartilage homeostasis through PI3K/Akt signaling [25], but TRIM3 likely operates at a more upstream regulatory level. Reports that MFN2 overexpression causes metabolic disorders by inhibiting PI3K/AKT/mTOR [26] provide new perspectives for understanding the metabolic basis of TRIM3-ECM regulation. Notably, recent studies on BPA regulating mitophagy via the PTEN/PI3K/AKT/mTOR pathway [27] suggest TRIM3 may influence ECM synthesis by modulating mitochondrial quality control—a hypothesis requiring further validation. This study shares methodological limitations common to most OA mechanism research. For instance, the phenomenon where GDC-0349 still induces apoptosis in Akt1 knockout cells [28] suggests the importance of AKT/mTOR-independent pathways may be underestimated. Future studies could adopt: 1) The bidirectional validation strategy of Sox8 regulating autophagy via PI3K/AKT/mTOR [29]; 2) The multi-pathway interaction analysis framework of ERK1/2MAPK/Akt/mTOR/IRF3 cascades in keratinocytes [30]. These discoveries suggest new targeted strategy ideas for OA treatment: Compared to traditional broad-spectrum AKT/mTOR inhibitors, precise regulation of TRIM3 may achieve better risk–benefit ratios. Particularly for combination therapies, reference could be made to: 1) Curcumin and Probucol's synergistic regulation of apoptosis/autophagy balance via the PI3K-Akt-mTOR pathway [31]; or 2) The synergistic effects of TBMS1 and TMZ co-inhibiting the EGFR/PI3K/Akt/mTOR/NF-κB pathway [32]. Although this study reveals the potential mechanism by which TRIM3 influences chondrocyte apoptosis through the AKT/mTOR signaling pathway, several limitations still need to be addressed in future research. First, the sample size of clinical tissues used in this study was relatively small, which may affect the statistical power of the results. Future studies should expand the sample size or incorporate multicenter clinical data to further validate the role of TRIM3 in osteoarthritis progression. Second, regarding apoptosis analysis, this study lacks ultrastructural evidence such as transmission electron microscopy (TEM) observation of apoptotic bodies and does not comprehensively examine the expression profiles of apoptosis-related genes (e.g., Caspase 3, PARP). Instead, it only assesses apoptosis trends through changes in the Bcl-2/Bax ratio, which may not fully capture the impact of TRIM3 on apoptotic pathways. Furthermore, although this study suggests that TRIM3 may promote chondrocyte apoptosis by suppressing the AKT/mTOR pathway, it only preliminarily explores a few key molecules (e.g., p-AKT, p-mTOR) without in-depth analysis of the upstream and downstream regulatory networks. Therefore, future studies should employ more systematic in vivo and in vitro experiments (e.g., gene knockout animal models, single-cell sequencing) to further elucidate the precise regulatory mechanism of TRIM3 in chondrocyte apoptosis. In summary, the findings of this study provide new experimental evidence for the role of TRIM3 in osteoarthritis, but its molecular mechanisms still require deeper exploration. Future research should integrate multi-omics analysis and functional experiments to comprehensively decipher the regulatory network of TRIM3 in cartilage degeneration, thereby offering novel insights for targeted therapy of osteoarthritis. Conclusion This research reveals the potential mechanism of TRIM3 in cartilage degeneration in osteoarthritis. We found that TRIM3 may promote chondrocyte apoptosis and regulate chondrocyte matrix metabolism by inhibiting the AKT/mTOR signaling pathway, thereby promoting cartilage degeneration. These findings provide a new perspective for a deeper understanding of the pathological mechanism of osteoarthritis and suggest that TRIM3 may be a potential therapeutic target for osteoarthritis. Future research can further explore the role of TRIM3 in in vivo cartilage degeneration models and evaluate its feasibility as a therapeutic target.